Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group

Origins of STIL‐TAL1 fusion genes in children who later developed paediatric T‐cell acute lymphoblastic leukaemia: An investigation of neonatal blood spots

“…and D'Angio et al., STIL‐TAL1 was reported to be more common in males than in females, which theoretically would increase the likelihood of positive cases in our material . Similarly, high levels of white blood cells (WBCs) at diagnosis in patients positive for STIL‐TAL1 have been reported by several studies . In our material, a total of eighteen patients had WBC > 100 × 10 9 /l, which further indicates this to be a suitable patient group for STIL‐TAL1 analysis.…”

“…However, in studies by Mansur et al. and D'Angio et al., STIL‐TAL1 was reported to be more common in males than in females, which theoretically would increase the likelihood of positive cases in our material . Similarly, high levels of white blood cells (WBCs) at diagnosis in patients positive for STIL‐TAL1 have been reported by several studies .…”

“…Approximately 11‐27 % of children with T‐ALL present with the genetic aberration SCL/TAL1 interrupting locus ( STIL )‐T‐cell acute leukaemia ( TAL1 ) at diagnosis . STIL‐TAL1 fusion is exclusively found in T‐ALLs and based on single cell phylogenomics, is considered to be an early or initiating event in T‐ALL …”

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

“…Patients with an elevated WBC count ($100 3 10 9 /L) are more likely to have certain genetic aberrations, such as SIL-TAL1 fusions, [45][46][47] and have a different response to treatment, with more frequent poor PR and slower MRD clearance, although the prognostic value of the WBC count often loses independent discrimination on multivariate analysis with MRD. 5,7,35,47 This was not the case here, when a WBC count $200 3 10 9 /L at diagnosis proved to be an independent, albeit weaker, risk factor, in addition to MRD and the oncogenetic classifier.…”

The impact of immunological and biomolecular investigations on the outcome of children with acute lymphoblastic leukemia - experience of IIIrd Paediatric Clinic Timisoara

“…Patients exhibiting the E2A-PBX1 gene fusion, presented late relapses, after more than 3 years after the diagnosis. Different studies showed controversial results with respect to the prognosis of the patients SIL-TAL rearrangements (30)(31)(32). In the present study, early relapses after diagnosis were registered for the patients having SIL-TAL rearrangements: one patient presented relapse in less than one year from the diagnosis, the other two patients relapsed between one year and two years after the moment of diagnosis.…”